Eli Lilly's Orforglipron Data Is Not Disastrous: Analyst

Eli Lilly and Co (NYSE:LLY) released underwhelming data from a Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.

For the primary endpoint, orforglipron 36 mg lowered weight by an average of 12.4% (27.3 lbs) compared to 0.9% (2.2 lbs) with placebo using the efficacy estimand, below Wall Street’s expectations of around 15%.

Eli Lilly also released better-than-expected second-quarter earnings on Thursday and raised 2025 guidance.

Bank of America (BofA) Securities said on Friday that the second quarter was strong. Mounjaro and Zepbound were meaningfully ahead of consensus.

Also Read: Eli Lilly’s ...